Fig. 1

The progression-free survival (PFS) (a) and overall survival (OS) (b) were similar between the patients receiving 30 mg and 40 mg daily of afatinib (median PFS: 469 vs. 443 days, log-rank p = 0.8418; log-rank p = 0.3522 for OS)
The progression-free survival (PFS) (a) and overall survival (OS) (b) were similar between the patients receiving 30 mg and 40 mg daily of afatinib (median PFS: 469 vs. 443 days, log-rank p = 0.8418; log-rank p = 0.3522 for OS)